1
|
Xiao Y, Jiang Y, Song H, Liang T, Li Y,
Yan D, Fu Q and Li Z: RNF7 knockdown inhibits prostate cancer
tumorigenesis by inactivation of ERK1/2 pathway. Sci Rep.
7:436832017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Liu Y, Liu Y, Yuan B, Yin L, Peng Y, Yu X,
Zhou W, Gong Z, Liu J, He L, et al: FOXM1 promotes the progression
of prostate cancer by regulating PSA gene transcription.
Oncotarget. 8:17027–17037. 2017.PubMed/NCBI
|
3
|
Han J, Song J, Li X, Zhu M, Guo W, Xing W,
Zhao R, He X, Liu X, Wang S, et al: Ligustrazine suppresses the
growth of HRPC cells through the inhibition of Cap-dependent
translation via both the mTOR and the MEK/ERK pathways. Anticancer
Agents Med Chem. 15:764–772. 2015. View Article : Google Scholar : PubMed/NCBI
|
4
|
Fu YS, Lin YY, Chou SC, Tsai TH, Kao LS,
Hsu SY, Cheng FC, Shih YH, Cheng H, Fu YY, et al:
Tetramethylpyrazine inhibits activities of glioma cells and
glutamate neuro-excitotoxicity: Potential therapeutic application
for treatment of gliomas. Neuro Oncol. 10:139–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Wang XB, Wang SS, Zhang QF, Liu M, Li HL,
Liu Y, Wang JN, Zheng F, Guo LY and Xiang JZ: Inhibition of
tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug
resistant human hepatocellular carcinoma cells. Oncol Rep.
23:211–215. 2010.PubMed/NCBI
|
6
|
Wang Y, Fu Q and Zhao W:
Tetramethylpyrazine inhibits osteosarcoma cell proliferation via
downregulation of NF-κB in vitro and in vivo. Mol Med
Rep. 8:984–988. 2013.PubMed/NCBI
|
7
|
Yi B, Liu D, He M, Li Q, Liu T and Shao J:
Role of the ROS/AMPK signaling pathway in
tetramethylpyrazine-induced apoptosis in gastric cancer cells.
Oncol Lett. 6:583–589. 2013.PubMed/NCBI
|
8
|
Yin J, Yu C, Yang Z, He JL, Chen WJ, Liu
HZ, Li WM, Liu HT and Wang YX: Tetramethylpyrazine inhibits
migration of SKOV3 human ovarian carcinoma cells and decreases the
expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling
pathways. Oncol Rep. 26:671–679. 2011.PubMed/NCBI
|
9
|
Zhang Y, Liu X, Zuo T, Liu Y and Zhang JH:
Tetramethylpyrazine reverses multidrug resistance in breast cancer
cells through regulating the expression and function of
P-glycoprotein. Med Oncol. 29:534–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Zheng CY, Xiao W, Zhu MX, Pan XJ, Yang ZH
and Zhou SY: Inhibition of cyclooxygenase-2 by tetramethylpyrazine
and its effects on A549 cell invasion and metastasis. Int J Oncol.
40:2029–2037. 2012.PubMed/NCBI
|
11
|
Sanders DA, Ross-Innes CS, Beraldi D,
Carroll JS and Balasubramanian S: Genome-wide mapping of FOXM1
binding reveals co-binding with estrogen receptor alpha in breast
cancer cells. Genome Biol. 14:R62013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ahmed M, Hussain AR, Siraj AK, Uddin S,
Al-Sanea N, Al-Dayel F, Al-Assiri M, Beg S and Al-Kuraya KS:
Co-targeting of cyclooxygenase-2 and FoxM1 is a viable strategy in
inducing anticancer effects in colorectal cancer cells. Mol Cancer.
14:1312015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhang N, Xie Y, Li B, Ning Z, Wang A and
Cui X: FoxM1 influences mouse hepatocellular carcinoma metastasis
in vitro. Int J Clin Exp Pathol. 8:2771–2778. 2015.PubMed/NCBI
|
14
|
Zhang J, Zhang J, Cui X, Yang Y, Li M, Qu
J, Li J and Wang J: FoxM1: A novel tumor biomarker of lung cancer.
Int J Clin Exp Med. 8:3136–3140. 2015.PubMed/NCBI
|
15
|
Yu J, Wang X, Li Y and Tang B: Tanshinone
IIA suppresses gastric cancer cell proliferation and migration by
downregulation of FOXM1. Oncol Rep. 37:1394–1400. 2017.PubMed/NCBI
|
16
|
Liu LP, Cao XC, Liu F, Quan MF, Sheng XF
and Ren KQ: Casticin induces breast cancer cell apoptosis by
inhibiting the expression of forkhead box protein M1. Oncol Lett.
7:1711–1717. 2014.PubMed/NCBI
|
17
|
Zhang Y, Li CF, Ma LJ, Ding M and Zhang B:
MicroRNA-224 aggrevates tumor growth and progression by targeting
mTOR in gastric cancer. Int J Oncol. 49:1068–1080. 2016.PubMed/NCBI
|
18
|
Kim HY, Cho Y, Kang H, Yim YS, Kim SJ,
Song J and Chun KH: Targeting the WEE1 kinase as a molecular
targeted therapy for gastric cancer. Oncotarget. 7:49902–49916.
2016.PubMed/NCBI
|
19
|
Kanda M, Shimizu D, Fujii T, Tanaka H,
Tanaka Y, Ezaka K, Shibata M, Takami H, Hashimoto R, Sueoka S, et
al: Neurotrophin receptor-interacting melanoma antigen-encoding
gene Homolog is associated with malignant phenotype of gastric
cancer. Ann Surg Oncol. 23:(Suppl 4). 532–539. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Kanda M, Shimizu D, Fujii T, Tanaka H,
Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, et
al: Protein arginine methyltransferase 5 is associated with
malignant phenotype and peritoneal metastasis in gastric cancer.
Int J Oncol. 49:1195–1202. 2016.PubMed/NCBI
|
21
|
Han TS, Hur K, Xu G, Choi B, Okugawa Y,
Toiyama Y, Oshima H, Oshima M, Lee HJ, Kim VN, et al: MicroRNA-29c
mediates initiation of gastric carcinogenesis by directly targeting
ITGB1. Gut. 64:203–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wang XJ, Xu YH, Yang GC, Chen HX and Zhang
P: Tetramethylpyrazine inhibits the proliferation of acute
lymphocytic leukemia cell lines via decrease in GSK-3β. Oncol Rep.
33:2368–2374. 2015.PubMed/NCBI
|
23
|
Jia Y, Wang Z, Zang A, Jiao S, Chen S and
Fu Y: Tetramethylpyrazine inhibits tumor growth of lung cancer
through disrupting angiogenesis via BMP/Smad/Id-1 signaling. Int J
Oncol. 48:2079–2086. 2016.PubMed/NCBI
|
24
|
Wang L, Zhang X, Cui G, Chan JY, Wang L,
Li C, Shan L, Xu C, Zhang Q, Wang Y, et al: A novel agent exerts
antitumor activity in breast cancer cells by targeting
mitochondrial complex II. Oncotarget. 7:32054–32064.
2016.PubMed/NCBI
|
25
|
Ji AJ, Liu SL, Ju WZ and Huang XE:
Anti-proliferation effects and molecular mechanisms of action of
tetramethypyrazine on human SGC-7901 gastric carcinoma cells. Asian
Pac J Cancer Prev. 15:3581–3586. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wang CY, Hua L, Sun J, Yao KH, Chen JT,
Zhang JJ and Hu JH: MiR-211 inhibits cell proliferation and
invasion of gastric cancer by down-regulating SOX4. Int J Clin Exp
Pathol. 8:14013–14020. 2015.PubMed/NCBI
|
27
|
Gormally MV, Dexheimer TS, Marsico G,
Sanders DA, Lowe C, Matak-Vinković D, Michael S, Jadhav A, Rai G,
Maloney DJ, et al: Suppression of the FOXM1 transcriptional
programme via novel small molecule inhibition. Nat Commun.
5:51652014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim
HK, Bae KB, Park YH, Kim SU, Kim JM, Kim N, et al: FOXM1-induced
PRX3 regulates stemness and survival of colon cancer cells via
maintenance of mitochondrial function. Gastroenterology.
149:1006–16.e9. 2015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Buchner M, Park E, Geng H, Klemm L, Flach
J, Passegué E, Schjerven H, Melnick A, Paietta E, Kopanja D, et al:
Identification of FOXM1 as a therapeutic target in B-cell lineage
acute lymphoblastic leukaemia. Nat Commun. 6:64712015. View Article : Google Scholar : PubMed/NCBI
|
30
|
Wiseman EF, Chen X, Han N, Webber A, Ji Z,
Sharrocks AD and Ang YS: Deregulation of the FOXM1 target gene
network and its coregulatory partners in oesophageal
adenocarcinoma. Mol Cancer. 14:692015. View Article : Google Scholar : PubMed/NCBI
|
31
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
32
|
Hui MK, Chan KW, Luk JM, Lee NP, Chung Y,
Cheung LC, Srivastava G, Tsao SW, Tang JC and Law S: Cytoplasmic
forkhead box M1 (FoxM1) in esophageal squamous cell carcinoma
significantly correlates with pathological disease stage. World J
Surg. 36:90–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
33
|
Zhang Z, Zhang G and Kong C: FOXM1
participates in PLK1-regulated cell cycle progression in renal cell
cancer cells. Oncol Lett. 11:2685–2691. 2016.PubMed/NCBI
|
34
|
Inoguchi S, Seki N, Chiyomaru T, Ishihara
T, Matsushita R, Mataki H, Itesako T, Tatarano S, Yoshino H, Goto
Y, et al: Tumour-suppressive microRNA-24-1 inhibits cancer cell
proliferation through targeting FOXM1 in bladder cancer. FEBS Lett.
588:3170–3179. 2014. View Article : Google Scholar : PubMed/NCBI
|